INM is a $4M market-cap shell whose value is purely a function of the Mentari merger closing. The FY2026 results confirm the company has no standalone path, cash is $2.2M with $1.8M in payables. Monitor for Form S-4 effectiveness and shareholder vote dates; deal failure would likely render INM equity worthless. The ~$490M pre-closing financing by Mentari provides a strong signal of institutional backing, but INM holders will be diluted into a small stub position in the combined entity.
INM drugs
INM drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Sep 10 $1.31entry
- T+1 · 2mo ago −1.53%α −2.38% · $1.29
- T+5 · 2mo ago +6.11%α +6.61% · $1.39
- T+20 · 6w ago +1.53%α −0.60% · $1.33
- T+47 · todayOpen
- T+60 · in 17d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
InMed Pharmaceuticals filed a Rule 425 communication reporting FY2026 annual results and providing a corporate update on its proposed merger with Mentari Therapeutics. The net loss widened to $12.6M from $8.2M, cash burned to $2.2M, and the company is a pre-revenue shell whose value is entirely tied to the pending reverse-merger into Mentari, which has raised ~$490M in pre-closing financing. The merger remains on track for Q4 2026 close, but InMed's standalone financials show a deteriorating cash position and no operating revenue, making this a binary event on deal completion.
Key Financial Metrics
Key Facts
- Net loss widened to $12.6M for FY2026 vs $8.2M in FY2025
- Cash and short-term investments fell to $2.2M from $10.7M year-over-year
- Merger with Mentari Therapeutics on track for Q4 2026 close; combined company to trade as MTRI
- Mentari raised ~$490M total pre-closing financing ($290M May + $200M July 2026)
- InMed's legacy pipeline (INM-901, INM-089, INM-755) to be monetized via CVR structure
- BayMedica subsidiary discontinued and wound down
- Form S-4 filed but not yet effective; shareholder votes pending
Financial Impact
Net loss of $12.6M on $0 revenue from continuing operations; cash burn of $8.6M from operations; cash runway effectively zero without merger proceeds
Risk Factors
- Merger fails to close, InMed has no revenue and insufficient cash to continue operations
- Shareholder or stockholder approval not obtained
- Form S-4 not declared effective by SEC
- Legacy InMed pipeline (CVRs) may never generate value
- Nasdaq continued-listing requirements may not be met
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001213900-26-098432 |
| Document: 0001213900-26-098432-index-headers.html | 0001213900-26-098432 |
| Document: 0001213900-26-098432-index.html | 0001213900-26-098432 |
| Document: 0001213900-26-098432.txt | 0001213900-26-098432 |
Track record
22 reports on INM
6 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +24.51% at T+1 after the Nov 3, 2026 report. 10 of 12 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $16.00 Now $19.87 +24.19% settles Dec 8
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 3, 202613d ago 8-K Bearish 6/10 Entry $1.75 Now $19.87 −1035.43% settles Dec 3
- Nov 2, 202614d ago 425 Neutral 3/10 Entry $1.68 Now $19.87 +1082.74% settles Dec 2
- Oct 26, 202621d ago 425 Neutral 3/10 Entry $1.59 Now $19.87 +1149.69% settles Nov 24
- Oct 7, 20265w ago SC 13G/A Bullish 5/10 Entry $1.33 to $1.32 Now $19.87 +1393.99% ▼ −0.68% +4.61% vs SPY
- Oct 2, 20266w ago EFFECT Neutral 3/10 Entry $1.33 to $1.60 Now $19.87 +1393.99% ▲ +20.30% +22.11% vs SPY
- Sep 18, 20268w ago 8-K Bearish 6/10 Entry $1.38 to $1.37 Now $19.87 −1339.86% ▲ +1.06% +0.15% vs SPY
- Sep 9, 20269w ago 425 Neutral 6/10 Viewing Entry $1.31 to $1.33 Now $19.87 +1416.79% ▲ +1.53% −0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers